{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T22:43:36Z","timestamp":1777761816465,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["1298\\u20131304"],"award-info":[{"award-number":["1298\\u20131304"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.semarthrit.2022.152134","type":"journal-article","created":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T17:35:48Z","timestamp":1668360948000},"page":"152134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7671-5748","authenticated-orcid":false,"given":"Emilce E.","family":"Schneeberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Citera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique R.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Helling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette E.","family":"Szumski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Mundayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dar\u00edo Ponce","family":"de Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2022.152134_bib0001","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0002","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0003","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0004","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s10067-014-2651-x","article-title":"Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria","volume":"33","author":"Ficco","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0006","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0007","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0008","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","article-title":"Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone","volume":"51","author":"Rosen","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0009","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/art.40391","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis\/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0012","article-title":"Classification and outcome measures for psoriatic arthritis","volume":"5","author":"Leung","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0013","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-017-0642-z","article-title":"The changing face of clinical trials in psoriatic arthritis","volume":"19","author":"Ogdie","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0014","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/rheumatology\/kez305","article-title":"Assessment of the many faces of PsA: single and composite measures in PsA clinical trials","volume":"59","author":"McGagh","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0015","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/art.37939","article-title":"Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease","volume":"65","author":"Coates","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0016","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1136\/annrheumdis-2015-208509","article-title":"The definition of remission in psoriatic arthritis: can this be accurate without assessment of multiple domains?","volume":"74","author":"Helliwell","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0017","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1136\/annrheumdis-2015-208521","article-title":"Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates","volume":"74","author":"Schoels","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0018","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/annrheumdis-2020-216999","article-title":"Use of multidimensional composite scores in rheumatology: parsimony versus subtlety","volume":"80","author":"Landew\u00e9","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0019","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0020","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3899\/jrheum.150826","article-title":"Defining low disease activity states in psoriatic arthritis using novel composite disease instruments","volume":"43","author":"Coates","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0021","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/acr.20155","article-title":"Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0022","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0023","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0024","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0025","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40744-020-00209-4","article-title":"Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL Balance, an open-label, long-term extension study","volume":"7","author":"Nash","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0026","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13075-018-1739-0","article-title":"Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease","volume":"20","author":"Helliwell","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0027","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semarthrit.2020.03.015","article-title":"Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study","volume":"50","author":"Coates","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0028","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/annrheumdis-2018-214140","article-title":"Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries","volume":"78","author":"Gorlier","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0029","series-title":"Practical Statistics for Medical Research","author":"Altman","year":"1991"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0030","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40744-018-0131-5","article-title":"Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two Phase 3 studies","volume":"5","author":"Nash","year":"2018","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0031","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.berh.2018.08.004","article-title":"Disease activity assessment in patients with psoriatic arthritis","volume":"32","author":"Kerschbaumer","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0032","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/annrheumdis-2016-209511","article-title":"Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression","volume":"76","author":"Aletaha","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0033","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3899\/jrheum.180460","article-title":"Very low disease activity, DAPSA remission, and impact of disease in a Spanish population with psoriatic arthritis","volume":"46","author":"Queiro","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0034","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"SPIRIT H2H study group. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0035","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/annrheumdis-2020-217372","article-title":"Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis na\u00efve to biological disease-modifying antirheumatic drug: final results by week 52","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0036","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.semarthrit.2017.10.021","article-title":"Considerations for the definition of remission criteria in psoriatic arthritis","volume":"47","author":"Mease","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0037","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/cei.12234","article-title":"Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis","volume":"175","author":"Migita","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0038","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1136\/annrheumdis-2019-215960","article-title":"DAPSA versus cDAPSA: do we need to use CRP?","volume":"79","author":"Gon\u00e7alves","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152134_bib0039","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:23:22Z","timestamp":1777472602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222001858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":39,"alternative-id":["S0049017222001858"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152134","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152134"}}